Bone biologics announces closing of registered direct offering priced at-the-market under nasdaq rules

Burlington, mass.--(business wire)--bone biologics corporation (nasdaq: bblg), a developer of orthobiologic products for spine fusion markets, today announced the closing of its previously announced registered direct offering priced at-the-market under nasdaq rules of an aggregate of 1,139,063 of its shares of common stock at a purchase price of $0.64 per share. in a concurrent private placement, the company also issued and sold unregistered warrants to purchase up to an aggregate of 1,139,063.
BBLG Ratings Summary
BBLG Quant Ranking